BIO-TECHNE Corp vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? BIO-TECHNE Corp trades at $72.45 (market cap $11.36B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.08 (market cap $3.80B). The key difference: BIO-TECHNE Corp is far larger — about 3× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| TECH | VNQI | |
|---|---|---|
Market Cap | $11.36B | $3.80B |
Volume | 5,390,331 | 277,049 |
Sector | Health | — |
52-Week High | $72.61 | $50.76 |
52-Week Low | $43.31 | $41.81 |
Typical Hold Time | 63 Days | 95 Days |
Enterprise Value | $11.39B | — |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
VNQI trades at $42.06, up 0.6% with a bearish technical signal from moving averages. The ETF focuses on international real estate across 30+ countries, offering diversification but facing recent price pressure below key moving averages. Short interest declined 45.9% in September (Defense World, 2026-10-02), potentially indicating reduced bearish sentiment despite the technical downtrend.
The outlook remains cautious given bearish technicals and international real estate exposure risks. Competitive advantages include lower expense ratios (0.12%) and higher dividend yields versus peers. Key risks involve global economic sensitivity and currency fluctuations affecting international holdings.
Trailing returns across standard periods
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →